Cardiac amyloidosis future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{RT}}; {{AN}} | {{CMG}}; {{AE}} {{RT}}; {{AN}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
==Overview== | ==Overview== | ||
New therapies targeting the serum amyloid protein (SAP), which is an excellent immunogen and a universal component of all amyloid deposits, using monoclonal antibodies are being investigated currently | New therapies targeting the serum amyloid protein (SAP), which is an excellent immunogen and a universal component of all amyloid deposits, using monoclonal antibodies are currently being investigated. | ||
==Future and Investigational Therapies== | |||
Possible future treatment options which are currently being investigated include: | |||
* Anti-SAP antibody | |||
* CPHPC | |||
==References== | ==References== |
Revision as of 16:56, 12 May 2013
Cardiac amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cardiac amyloidosis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Cardiac amyloidosis future or investigational therapies |
FDA on Cardiac amyloidosis future or investigational therapies |
CDC onCardiac amyloidosis future or investigational therapies |
Cardiac amyloidosis future or investigational therapies in the news |
Blogs on Cardiac amyloidosis future or investigational therapies |
Risk calculators and risk factors for Cardiac amyloidosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
New therapies targeting the serum amyloid protein (SAP), which is an excellent immunogen and a universal component of all amyloid deposits, using monoclonal antibodies are currently being investigated.
Future and Investigational Therapies
Possible future treatment options which are currently being investigated include:
- Anti-SAP antibody
- CPHPC